Rethinking prevention of HIV type 1 infection

Clinical Infectious Diseases

Volumn 51, Issue 6, 2010, Pages 725-731

  Burns, David N ^a   Dieffenbach , Carl W ^a   Vermund , Sten H ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MICROBICIDE; PLACEBO; TENOFOVIR DISOPROXIL;

ANTIVIRAL THERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; EPIDEMIC; HEALTH PROGRAM; HETEROSEXUAL FEMALE; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; MALE HOMOSEXUAL; MEDICAL RESEARCH; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL BEHAVIOR; VIRUS LOAD;

ANTI-HIV AGENTS; CHEMOPREVENTION; COMMUNICABLE DISEASE CONTROL; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MODELS, THEORETICAL; PANDEMICS;

EID: 77955953404     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/655889     Document Type: Review

References (63)

1. UNAIDS. Report on the global HIV/AIDS epidemic 2008. Geneva: UNAIDS, 2008. http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008- Global-report.asp. Accessed 5 February 2010.
2. UNAIDS. AIDS epidemic update: December 2009. Geneva: UNAIDS, 2009. http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2009/ default.asp. Accessed 5 February 2010.
3. Sullivan PS, Hamouda O, Delpech V, et al. Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996-2005. Ann Epidemiol 2009; 19: 423-431.
4. Marcus U, Voss L, Kollan C, Hamouda O. HIV incidence increasing in MSM in Germany: factors influencing infection dynamics. Euro Surveill 2006; 11:157-160.
5. Bezemer D, deWolf F, Boerlijst MC, et al. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS 2008; 22:1071-1077.
6. Centers for Disease Control and Prevention. Trends in HIV/AIDS diagnoses among men who have sex with men. MMWR Morb Mortal Wkly Rep 2008; 57:681-686.
7. Lagokos SW, Gable AR, eds. Methodological challenges in biomedical HIV prevention trials. Washington, DC: National Academies Press, 2008.
8. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 2010; 24:621-635.
9. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2: 487-493.
10. Lima VD, Johnston K, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008; 198:59-67.
11. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
12. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS ONE 2007; 9:e875. http://www.plosone.org/article/info:doi/10.1371/journal.pone. 0000875. Accessed 5 February 2010.
13. Paltiel AD, Freedberg KA, Scott CA, et al. HIV pre-exposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009; 48:806-815.
14. Karim QA, Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbe, for the prevention of HIV infection in women. Science 2010. http://www.sciencemag.org/cgi/content/abstract/science. 1193748v1. Accessed 24 July 2010.
15. Heymann SJ. Modelling the efficacy of prophylactic and curative therapies for preventing the spread of tuberculosis in Africa. Trans Royal Soc Trop Med Hygiene 1993; 87:406-411.
16. Blower SM, Small PM, Hopewell PC. Control strategies for tuberculosis epidemics: new models for old problems. Science 1996; 273:497-500.
17. Foster S, Godfrey-Faussett P, Porter J. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. AIDS 1997; 11:919-925.
18. Dye C, Fengzeng Z, Scheele S, Williams B. Evaluating the impact of tuberculosis control: number of deaths prevented by short course chemotherapy in China. Int J Epidemiol 2000; 29:558-564.
19. Manhart LE, Holmes KK. Randomized controlled trials of individual- level, population-level, and multilevel interventions for preventing sexually transmitted infections: what has worked? J Infect Dis 2005; 191(suppl 1):S7-S24.
20. Fang C-T, Hsu H-M, Twu S-J, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004; 190:879-885.
21. Castilla J, del Romero J, Hernando V, Marincovich B, García S, Rodri"guez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96-101.
22. Wood E, Kerr T, Marshall BDL, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009; 338:b1649. http://www.bmj.com/cgi/content/ full/338/apr30-1/b1649?viewplong&pmidp19406887. Accessed 5 February 2010.
23. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-1404
24. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-494.
25. HIV Prevention Trials Network. HPTN 052: A randomized trial to evaluate the effectiveness of antiretroviral therapy plus HIV primary care versus HIV primary care alone to prevent the sexual transmission of HIV-1 in serodiscordant couples. http://www.hptn.org/research-studies/hptn052.asp. Accessed 5 February 2010.
26. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: antiretroviral therapy in San Francisco. Science 2000; 287:650-654.
27. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission by stage of infection. J Infect Dis 2008; 198:687-693.
28. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 2010; 24:729-735.
29. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006; 20:1447-1450.
30. Centers for Disease Control and Prevention. HIV prevalence estimates- United States, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:1073-1076.
31. Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr 2010; 53:619-624.
32. Anand A, Shiraishi RW, Bunnell RE, et al. Knowledge of HIV status, sexual risk behaviors and contraceptive need among people living with HIV in Kenya and Malawi. AIDS 2009; 23:1565-1573.
33. Gardner LI, Metsch LR, Anderson-Mahoney P, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS 2005; 19:423-431.
34. Richardson JL. Dataset: Partnership for Health Study. Los Angeles CA: University of Southern California, 2001.
35. Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22:1951-1960.
36. Hull MW, Lima VD, Hogg RS, Harrigan PR, Montaner JS. Epidemiology of treatment failure: a focus on recent trends. Curr Opin HIV AIDS 2009; 4:467-473.
37. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1 December 2009. http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 5 February 2010.
38. Vermund SH, Hodder SL, Justman JE, et al. Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis 2010; 50(S3):S149-S155.
39. World Health Organization. Modelling the impact of antiretroviral therapy on TB and HIV: informal working group meeting, 4-6 November 2009, Geneva, Switzerland. http://www.who.int/hiv/topics/artforprevention/modelling-meeting/ en/index.html. Accessed 5 February 2010.
40. AVAC: Global Advocacy for HIV Prevention. Ongoing ARV-based prevention (oral PrEP and topical microbicide) trials (December 2009). http://www.avac.org/ ht/a/GetImageAction/i/4474. Accessed 5 February 2010.
41. HIV Prevention Trials Network. Ongoing studies and studies in development. http://hptn.org/research-studies.asp. Accessed 5 February2010.
42. International AIDS Vaccine Initiative. Studies evaluating the safety and acceptability of intermittent pre-exposure prophylaxis (PrEP) regimen. http://www.iavi.org/research-development/trials/Pages/Pr EPstudy.aspx. Accessed 5 February 2010.
43. Kwara A, Delong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 2008; 46: 719-725.
44. Vourvahis M, Tappouni HL, Patterson KB, et al. The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr 2008; 47:329-333.
45. García-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008; 5:e28. http://www.plosmedicine.org/ article/info:doi%2F10.1371%2Fjournal.pmed.0050028. Accessed 5 February 2010.
46. Stover J, Walker N, Garnett GP, et al. Can we reverse the HIV/AIDS pandemic with an expanded response? Lancet 2002; 360:73-77.
47. Horton R, Das P. Putting prevention at the forefront of HIV/AIDS. Lancet 2008; 372:421-422.
48. Madon T, Hofman KJ, Kupfer L, Glass RI. Implementation science. Science 2007; 318:1728-1729.
49. Guy R, Gold J, García Calleja JM, et al. Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis 2009; 9:747-759.
50. Sakarovitch C, Rouet F, Murphy G, et al. Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa? J Acquir Immune Defic Syndr 2007; 45:115-122.
51. Laeyendecker O, Rothman RE, Henson C, et al. The effect of viral suppression on cross-sectional incidence testing in the Johns Hopkins Hospital Emergency Department. J Acquir Immune Defic Syndr 2008; 48:211-215.
52. Marinda ET, Hargrove J, PreiserW, et al. Significantly diminished longterm specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 53:496-499.
53. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of carraguard for prevention of HIV infection in women in South Africa: a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372:1977-1987.
54. Watson-Jones D, Baisley K, Rusizoka M, et al. Measurement and predictors of adherence in a trial of HSV suppressive therapy in Tanzania. Contemp Clin Trials 2009; 30:504-512.
55. Masse BR, Boily M-C, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol 2009; 6:5. http://www.ete-online.com/content/6/1/5/abstract.Accessed 5 February 2010.
56. Cassell MM, Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 2006; 332: 605-607.
57. Eaton LA, Kalichman S. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007; 4:165-172.
58. Niska R, Han B. Anticoagulation for patients with atrial fibrillation in ambulatory care settings. J Am Board Fam Med 2009; 22:299-306.
59. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375:1014-1028.
60. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
61. Gupta GR, Parkhurst JO, Ogden JA, Aggleton P, Mahal A. Structural approaches to HIV prevention. Lancet 2008; 372:764-775.
62. Vermund SH, Karim QA. HIV prevention at a crossroads: advances in reducing sexual risk. Curr Opin HIV AIDS 2009; 4:266-273.
63. Hecht R, Bollinger L, Stover J, et al. Critical choices in financing the response to the global HIV/AIDS pandemic. Health Aff (Millwood) 2009; 28:1591-1605.